SWOG clinical trial number
SWOG-9429

Phase II Trial of Carboplatin and VP-16 With Concurrent For Poor-Risk Stage III Non-Small Cell Lung Carcinoma

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Phase II Trial of Carboplatin and VP-16 With Concurrent For Poor-Risk Stage III Non-Small Cell Lung Carcinoma
Activated
08/15/1994
Closed
09/01/1995

Research committees

Lung Cancer

Publication Information Expand/Collapse

2019

Clinical prognostic model for older patients with advanced non-small cell lung cancer

AK Ganti;X Wang;T Stinchcombe;Y Wang;J Bradley;HJ Cohen;K Kelly;R Paulus;SS Ramalingam;EE Vokes;H Pang Journal of Geriatric Oncology Feb 20. pii: S1879-4068(18)30197-8. doi: 10.1016/j.jgo.2019.02.007. [Epub ahead of print]

PMid: PMID30797707

1998

Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide and radiation for poor-risk stage III non-small cell lung cancer.

DH Lau;JJ Crowley;DR Gandara;MB Hazuka;KS Albain;B Leigh;WS Fletcher;KS Lanier;LW Keiser;RB Livingston Journal of Clinical Oncology 16(9):3078-3081

1997

A Southwest Oncology Group (SWOG) phase II trial: carboplatin and VP-16 with concurrent radiation for poor risk stage III non-small cell lung cancer.

DH Lau;D Gandara;M Hazuka;J Crowley;R Livingston Proc of the American Society of Clinical Oncology 16:449a(#1612)

Other Clinical Trials

SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)

Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007